ES2851123T1 - Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva - Google Patents

Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva Download PDF

Info

Publication number
ES2851123T1
ES2851123T1 ES20196219T ES20196219T ES2851123T1 ES 2851123 T1 ES2851123 T1 ES 2851123T1 ES 20196219 T ES20196219 T ES 20196219T ES 20196219 T ES20196219 T ES 20196219T ES 2851123 T1 ES2851123 T1 ES 2851123T1
Authority
ES
Spain
Prior art keywords
seq
lymphocytes
cells
cancer
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES20196219T
Other languages
English (en)
Inventor
Andras Heczey
Stephen M G Gottschalk
Leonid S Metelitsa
Gianpietro Dotti
Wenpeng Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of ES2851123T1 publication Critical patent/ES2851123T1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/464471—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464474—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/56—Kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Linfocitos T que expresan un receptor quimérico de antígeno (CAR) que se dirige a glipicano-3 (GPC3) para su uso en un método de tratamiento de una enfermedad asociada con la proliferación y/o actividad de células GPC3 positivas en un individuo, comprendiendo el método la etapa de poner en contacto las células con una cantidad terapéuticamente eficaz de los linfocitos T y comprendiendo el CAR (i) un anticuerpo scFv distinto de 3E11, 2G9, 4G5, 3D8 o 2E10 y (ii) un dominio coestimulante de CD28, en donde: (a) los linfocitos T albergan un polinucleótido que codifica el CAR y comprende la SEQ ID NO: 19, SEQ ID NO: 33, SEQ ID NO: 12 o SEQ ID NO: 29, o una combinación de las mismas; y/o (b) la CAR comprende la secuencia de aminoácidos de la SEQ ID NO: 18, SEQ ID, SEQ ID NO: 32, SEQ ID NO: 10 o SEQ ID NO: 28, o una combinación de las mismas; en donde la enfermedad es cáncer o síndrome de Simpson-Golabi-Behmel.

Claims (8)

REIVINDICACIONES
1. Linfocitos T que expresan un receptor quimérico de antígeno (CAR) que se dirige a glipicano-3 (GPC3) para su uso en un método de tratamiento de una enfermedad asociada con la proliferación y/o actividad de células GPC3 positivas en un individuo, comprendiendo el método la etapa de poner en contacto las células con una cantidad terapéuticamente eficaz de los linfocitos T y comprendiendo el CAR (i) un anticuerpo scFv distinto de 3E11, 2G9, 4G5, 3D8 o 2E10 y (ii) un dominio coestimulante de CD28, en donde:
(a) los linfocitos T albergan un polinucleótido que codifica el CAR y comprende la SEQ ID NO: 19, SEQ ID NO: 33, s Eq ID NO: 12 o SEQ ID NO: 29, o una combinación de las mismas; y/o
(b) la CAR comprende la secuencia de aminoácidos de la SEQ ID NO: 18, SEQ ID, SEQ ID NO: 32, SEQ ID NO: 10 o SEQ ID NO: 28, o una combinación de las mismas;
en donde la enfermedad es cáncer o síndrome de Simpson-Golabi-Behmel.
2. Los linfocitos T para el uso de la reivindicación 1, en donde las células GPC3 positivas son células cancerosas y: (a) el cáncer es cáncer de hígado, sarcoma embrionario, tumor rabdoide, tumor de Wilms, coriocarcinoma o tumor del saco vitelino; o
(b) dichas células cancerosas no son células de carcinoma hepatocelular.
3. Los linfocitos T para el uso de la reivindicación 1 o 2, en donde:
(a) dicho contacto se realiza in vitro; o
(b) dicho contacto se realiza en cultivo celular.
4. Los linfocitos T para el uso de la reivindicación 1 o 2, en donde dicho contacto se realiza in vivo.
5. Los linfocitos T para el uso de la reivindicación 4, en donde:
(a) dichos linfocitos T son autólogos para el individuo; o
(b) dichos linfocitos T son alogénicos para el individuo.
6. Los linfocitos T para el uso de una cualquiera de las reivindicaciones 1, 3(b), 4 y 5, en donde las células GPC3 positivas son células cancerosas, en donde además el individuo ha recibido, está recibiendo o recibirá un tratamiento adicional contra el cáncer.
7. Los linfocitos T para el uso de la reivindicación 6, en donde el tratamiento adicional contra el cáncer comprende quimioterapia, inmunoterapia, radiación, cirugía, hormonoterapia o una combinación de las mismas.
8. Los linfocitos T para el uso de una cualquiera de las reivindicaciones anteriores, en donde el polinucleótido comprende además un gen suicida.
ES20196219T 2014-09-26 2015-09-25 Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva Pending ES2851123T1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462055979P 2014-09-26 2014-09-26

Publications (1)

Publication Number Publication Date
ES2851123T1 true ES2851123T1 (es) 2021-09-03

Family

ID=55582053

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15845117T Active ES2844700T3 (es) 2014-09-26 2015-09-25 Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva
ES20196219T Pending ES2851123T1 (es) 2014-09-26 2015-09-25 Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES15845117T Active ES2844700T3 (es) 2014-09-26 2015-09-25 Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva

Country Status (6)

Country Link
US (1) US20170281683A1 (es)
EP (2) EP3858991A1 (es)
JP (1) JP2017529851A (es)
DE (1) DE20196219T1 (es)
ES (2) ES2844700T3 (es)
WO (1) WO2016049459A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11434294B2 (en) 2016-02-25 2022-09-06 Cell Medica, Inc. Binding members to PD-L1
JP7145761B2 (ja) * 2016-04-22 2022-10-03 クレイジュ・メディカル・カンパニー・リミテッド 細胞免疫療法の組成物および方法
JP2019530431A (ja) 2016-07-26 2019-10-24 テッサ・セラピューティクス・プライベート・リミテッド キメラ抗原受容体
JP2018093823A (ja) * 2016-12-15 2018-06-21 Ｈｅａｒｔｓｅｅｄ株式会社 未分化幹細胞除去剤及び未分化幹細胞除去方法
WO2018131586A1 (ja) 2017-01-10 2018-07-19 国立大学法人山口大学 抗ｇｐｃ３抗体
AU2018258049A1 (en) * 2017-04-26 2019-12-12 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
EP3441461A1 (en) * 2017-08-11 2019-02-13 Baylor College of Medicine Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
MX2020013977A (es) 2018-06-22 2021-06-15 Kite Pharma Inc Proteínas quiméricas transmembrana y usos de las mismas.
US20210261646A1 (en) * 2018-07-03 2021-08-26 Sotio, LLC Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
CN112469829B (zh) * 2018-07-17 2023-07-07 诺伊尔免疫生物科技株式会社 包含抗gpc3单链抗体的car
BR112021001694A2 (pt) * 2018-08-14 2021-05-04 Sotio, LLC polipeptídeos do receptor de antígeno quimérico em combinação com moléculas de metabolismo trans que modulam o ciclo de krebs e seus usos terapêuticos
EP3860716A2 (en) 2018-10-01 2021-08-11 Adicet Bio Inc. Compositions and methods regarding engineered and non-engineered gamma-delta -t cells for treatment of solid tumors
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
AU2019374828A1 (en) * 2018-11-07 2021-05-27 Sotio, LLC Anti-GPC3 chimeric antigen receptors (CARs) in combination with trans co-stimulatory molecules and therapeutic uses thereof
US20220056092A1 (en) 2018-12-11 2022-02-24 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
SG11202109172TA (en) 2019-03-08 2021-09-29 Obsidian Therapeutics Inc Human carbonic anhydrase 2 compositions and methods for tunable regulation
CN113646426A (zh) * 2019-04-04 2021-11-12 上海医药集团股份有限公司 一种包含肿瘤抗原识别受体的免疫细胞及其应用
US20220267398A1 (en) 2019-06-12 2022-08-25 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
KR20220044266A (ko) 2019-06-12 2022-04-07 옵시디안 테라퓨틱스, 인크. 조정 가능한 조절을 위한 ca2 조성물 및 방법
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US20230146706A1 (en) * 2020-03-18 2023-05-11 Eutilex Co., Ltd. Gpc3 car- t cell compositions and methods of making and using the same
CA3176125A1 (en) * 2020-03-18 2021-09-23 Eutilex Co., Ltd. Gpc3 car- t cells secreting il-18 and methods of making and using the same
CA3188656A1 (en) 2020-07-17 2022-01-20 Simurx, Inc. Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
EP4321533A1 (en) 2021-04-08 2024-02-14 Crage Medical Co., Limited Cellular immunotherapy use
WO2023091909A1 (en) * 2021-11-16 2023-05-25 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
RU2395519C2 (ru) * 2005-08-09 2010-07-27 Онкотерапи Сайенс, Инк. Глипикан-3 (gpc3)-производные антигенные пептиды, отторгающие опухоли, используемые для нla-a2-положительных пациентов, и фармацевтическая продукция, включающая их
EP3070104B1 (en) * 2011-04-19 2017-12-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
EP2755487B1 (en) * 2011-09-16 2018-12-19 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
US20160000842A1 (en) * 2013-03-05 2016-01-07 Baylor College Of Medicine Oncolytic virus
CN107460201A (zh) * 2013-05-08 2017-12-12 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
AU2016304060B2 (en) * 2015-08-03 2022-09-29 Crage Medical Co., Limited Antibody against glypican-3 and application thereof

Also Published As

Publication number Publication date
US20170281683A1 (en) 2017-10-05
EP3198010A4 (en) 2018-06-06
JP2017529851A (ja) 2017-10-12
ES2844700T3 (es) 2021-07-22
WO2016049459A1 (en) 2016-03-31
DE20196219T1 (de) 2021-10-28
EP3198010B1 (en) 2020-11-04
EP3198010A1 (en) 2017-08-02
EP3858991A1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
ES2851123T1 (es) Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
AR127117A2 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
CL2019003310A1 (es) Nuevos péptidos (seq id no:1) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer. (divisional solicitud 201800124)
EP4219690A3 (en) Methods of cancer treatment using activated t cells
MX2020011744A (es) Molecula de polipeptido con especificidad dual mejorada.
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
MX2022005955A (es) Metodos y composiciones para terapia celular adoptiva.
MX2023005612A (es) Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
MY189028A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
NZ725201A (en) Improved methods for manufacturing adoptive cell therapies
EA202192024A1 (ru) Рецепторы, обеспечивающие прицельную костимуляцию, для адоптивной клеточной терапии
MX2017005344A (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
EA201270734A1 (ru) Антитела, реактивные к в7-н3, их иммунологически активные фрагменты и их применения
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
PE20180259A1 (es) Nuevos peptidos y combinacion de peptidos para usar en inmunoterapia contra el cancer esofagico y otros canceres
RU2021132734A (ru) Химерные рецепторы антигена, нацеленные на psca
BR112022025295A2 (pt) Células natural killer modificadas geneticamente para imunoterapia do câncer direcionada a cd70
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
CL2019003425A1 (es) Nuevos péptidos (seq id n°42), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
AU2018449846A8 (en) An anti-B7-H3 antibody